The White House today announced landmark drug pricing agreements with Eli Lilly and Company and Novo Nordisk to lower the ...

The U.S. has introduced a new pilot program to allow State and federally backed Medicaid healthcare programs to buy medicines ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

According to the White House, Novo Nordisk's semaglutide-based Ozempic for diabetes and Wegovy for obesity will cost $350 per ...

Experts analyze how Trump's drug pricing policies, including Most Favored Nation (MFN) and tariffs, reshape pharma markets and impact patient costs and access.

On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions ...

The Trump administration on Thursday announced its newest pharmaceutical agreement under its Most Favored Nation (MFN) policy, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 ...

At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had reached a "deal" on most-favoured nations drug ...

The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through ...

In the third entry of Pharmacuetical Executive’s premium webinar series examining the impact of President Trump’s MFN ...

A proposal tying U.S. drug prices to those of foreign nations would close clinics and diminish options for patients.

Compared to ABBV, PFE's latest dividend declarations and earnings report reveal growth pressure, high payout ratios, and ...